What is the common examiner trap about Economy in UPSC exams?

They may swap the tariff percentage (e.g., 50% instead of 100%), confuse the effective date, or ask about the impact on 'patented' vs 'generic' drugs to test careful reading. A trap could be a statement saying 'India's pharma exports are primarily patented,' which is false (they are primarily generic).

What should UPSC aspirants remember about Economy for Prelims?

1. Target this Data: 100% tariff on patented pharma from July 31, 2026. 2. Target this Data: India's pharma exports to US were $9.7 billion in 2025, constituting 38% of global exports. 3. Target this Nodal Body: US Department of Commerce (Secretary found threat to national security). 4. Target this Scheme: PLI Scheme for Pharmaceuticals with Rs 15,000 crore outlay (2021-2028).

EconomyInternational Relations

Take AI Challenge ▸

News 0 of 32

US Imposes 100% Tariff on Patented Pharma from July 31; India's $9.7 Billion Exports Mainly Generic

Q: The PLI Scheme for Pharmaceuticals, mentioned in the article, was approved by which Indian constitutional body?

The Union Cabinet, The article explicitly states: 'The PLI Scheme for Pharmaceuticals was approved by the Union Cabinet in 2021...' The Union Cabinet, chaired by the Prime Minister, is the supreme executive decision-making body of the Government of India.

Q: Consider the following statements regarding the US tariff announcement: 1. The 100% tariff applies to both patented and generic pharmaceutical imports from all countries. 2. The US Department of Commerce cited threats to national security and the economy as the rationale for the tariff. 3. India's Sun Pharma reported global sales of over $1.2 billion from patented products in FY25, with the US market accounting for a majority share. Which of the statements given above is/are correct?

Both 2 and 3, Statement 1 is incorrect: The tariff is specifically on patented pharmaceuticals and ingredients, and generic drugs are exempt 'at this time'. Statement 2 is correct as per the article: 'The Secretary [of Commerce] found that...imports...threaten to impair the national security and economy.' Statement 3 is correct: The article states Sun Pharma reported global sales of '$1,217 million from patented products in FY25, of which the US market accounted for 85-90%'.

Q: According to the article, what was the value of India's pharmaceutical exports to the United States in the year 2025?

$9.7 billion, The article directly quotes Ajay Srivastava: 'In 2025, India exported $9.7 billion worth of pharmaceuticals to the US...' $1.2 billion refers to Sun Pharma's patented product sales. $25.8 billion is India's global pharma exports.

Q: What is the primary strategic objective behind the US imposing tariffs on patented pharmaceuticals, as suggested by trade experts in the article?

To pressure drugmakers to lower prices in the US and shift some manufacturing locally., The article states: 'Trade experts said the US could use tariffs mainly as a pressure tool, not to raise revenue but to push drugmakers to cut prices in the US, shift some manufacturing locally, and to gain greater control over critical pharmaceutical supply chains...' The other options are not supported as the primary objective by the article's content.

Economy Intl. RelationsHIGH

Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link

03 Apr 2026

~2 min

Source: Indian Express

Key Data:100% tariffJuly 31, 2026$9.7 billion38% shareRs 15,000 crore$1,217 million

Bodies:US Department of CommerceUnion Cabinet

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.US President Donald Trump announced a 100% tariff on patented pharmaceuticals and ingredients effective July 31, 2026, under national security grounds.

2.India's pharma exports to the US, worth $9.7 billion in 2025, are 90% generic drugs and thus largely exempt, limiting immediate impact.

3.The move signals a strategic shift in treating pharma supply chains like semiconductors, using tariffs as a tool to lower US drug prices and relocate production.

The Big Picture

Prelims · HighMains · Medium

The US has imposed a 100% ad valorem tariff on imported patented pharmaceuticals from July 31, citing national security concerns over supply chain reliance. For India, the immediate impact is limited as 90% of its $9.7 billion pharma exports to the US are generic drugs, which are currently exempt. The strategic concern lies in future uncertainty and the US's potential use of tariffs to pressure price cuts and onshore manufacturing.

Exam Lens

Quick Exam Facts From News

Tariff Rate100% ad valorem

Effective DateJuly 31, 2026

India's Pharma Exports to US (2025)$9.7 billion

Share of India's Global Pharma Exports to US (2025)38%

PLI Scheme Outlay (2021)Rs 15,000 crore

1-Minute Revision

›Tariff Rate: 100% ad valorem
›Effective Date: July 31, 2026
›Target this Data: 100% tariff on patented pharma from July 31, 2026.
›Target this Data: India's pharma exports to US were $9.7 billion in 2025, constituting 38% of global exports.
›Target this Nodal Body: US Department of Commerce (Secretary found threat to national security).
›Target this Scheme: PLI Scheme for Pharmaceuticals with Rs 15,000 crore outlay (2021-2028).

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

⚖️

National Security Tariff

The US invoked the national security clause to impose a 100% tariff on patented pharma imports, aiming to secure its medical supply chain.

💊

India's Generic Shield

India's pharma exports to the US are largely shielded as 90% are generic drugs, which are exempt from the new tariff 'at this time'.

🎯

Strategic Pressure Tool

Experts view the tariff not as a revenue measure but as a strategic tool to force drug price cuts in the US and shift manufacturing locally.

Detailed Analysis & Strategic Depth

Context / Background

The US decision stems from a perceived vulnerability in its pharmaceutical supply chain, heavily reliant on imports. This mirrors recent strategic moves in sectors like semiconductors, where supply chain resilience is treated as a national security imperative. India, as the 'pharmacy of the world', has historically focused on generics but is now pushing into patented drugs through schemes like the PLI for Pharmaceuticals.

Core Analysis & Implications

The immediate impact on India is minimal ($9.7 billion exports, 90% generic). However, the policy targets India's strategic ambition to move up the value chain into patented drugs. Sun Pharma, with $1.2 billion in global patented sales (85-90% from US), is directly exposed. The larger risk is the precedent and future extension to generics, which would severely impact India's core export segment. The US action could accelerate global 'friend-shoring' of pharma production.

Future Outlook / Way Forward

The US will review extending tariffs to generic drugs within a year. India must leverage this window to strengthen its PLI Scheme for Pharmaceuticals (Rs 15,000 crore outlay till FY28) to build domestic capacity in biopharmaceuticals and complex generics. Diplomatic engagement is crucial to highlight India's role as a reliable supplier and to seek permanent exemptions for generics, framing it as essential for global health security.

Key Facts at a Glance

Tariff Rate100% ad valorem

Effective DateJuly 31, 2026

India's Pharma Exports to US (2025)$9.7 billion

Share of India's Global Pharma Exports to US (2025)38%

PLI Scheme Outlay (2021)Rs 15,000 crore

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, State PSC

The PLI Scheme for Pharmaceuticals, mentioned in the article, was approved by which Indian constitutional body?

Q2Statement-basedHardUPSC, SSC

Consider the following statements regarding the US tariff announcement:

1. The 100% tariff applies to both patented and generic pharmaceutical imports from all countries.

2. The US Department of Commerce cited threats to national security and the economy as the rationale for the tariff.

3. India's Sun Pharma reported global sales of over $1.2 billion from patented products in FY25, with the US market accounting for a majority share.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, Banking, SSC

According to the article, what was the value of India's pharmaceutical exports to the United States in the year 2025?

Q4Application/ImpactMediumUPSC, SSC, Banking

What is the primary strategic objective behind the US imposing tariffs on patented pharmaceuticals, as suggested by trade experts in the article?

All 25 MCQs ▸

Read original article from Indian Express

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

EconomyView Topic MCQs →Intl. RelationsView Topic MCQs →

Next Supreme Court Clarifies Article 324 Limits: ECI's Plenary Powers Cannot Override All India Services Act on Transfers

Related Current Affairs

Intl. Relations Current Affairs

US Imposes 100% Tariff on India Pharma Exports from 2028, Impact on $150 Bn Trade

Trump's unilateral tariff actions on Indian pharmaceutical exports (100% from 2028, rising to 200%) and use of Sections 301, 232, and 338 expose the fragility of ongoing India-US trade negotiations. Despite $150 billion bilateral trade and India's surplus, no signed agreement seems safe. India should prioritize trade diversification towards the UK and EU.

Economy Current Affairs

US Russia Sanctions Act: 100% Tariff on Russian Oil Imports Threatens India's Exports

The U.S. has enacted a law allowing up to 100% tariffs on countries like India that import Russian oil, a significant escalation from previous executive orders. This poses a direct threat to India's export competitiveness, particularly for MSMEs, and forces a strategic policy choice between diversifying energy sources or facing economic consequences.

Intl. Relations Current Affairs

India, New Zealand Sign FTA: Key Tariff Cuts on Dairy, Pharma & Trade Pact Details

India and New Zealand have signed a Free Trade Agreement (FTA) aimed at boosting bilateral trade. This editorial analyzes the strategic timing, sectoral impacts (dairy, pharma, services), and the geopolitical context of the deal, which is crucial for understanding India's evolving trade policy and its implications for domestic industries.

Intl. Relations Current Affairs

US Imposes 50% Tariffs on $20 Billion Canadian Goods; Canada Retaliates Under Section 338 of Tariff Act 1930

The US has imposed 50% tariffs on $20 billion worth of Canadian imports, invoking a rarely-used Depression-era law (Section 338, Tariff Act 1930). Canada immediately retaliated dollar-for-dollar, escalating a trade war that threatens the renewal of the USMCA trade pact. This is critical for understanding modern trade protectionism, legal instruments for tariffs, and the fragility of bilateral economic alliances.

Economy Current Affairs

European Commission Proposes India-EU FTA Approval: 96% Tariff Cut, €4 Billion Annual Savings

The European Commission has forwarded the India-EU FTA to the European Council for approval — the final stage before formal signing. If authorised, the deal will eliminate or reduce tariffs on 96% of EU goods exports to India, save about €4 billion annually in duties, and become the largest trade agreement ever concluded by both sides.

Intl. Relations Current Affairs

India Raises Concerns on US SRIA Law Allowing 100% Tariff on Russian Oil Buyers

India's External Affairs Minister S. Jaishankar met US Secretary of State Marco Rubio and conveyed India's concerns over the newly signed US 'Sanctioning Russia and Iran Act' (SRIA), which authorizes up to 100% tariffs on countries buying Russian oil and gas, including India. India reiterated its commitment to protect its economic interests and ensure energy security.

Intl. Relations Current Affairs

US-China Summit: 2-Month Trade Truce Extension, AI Safety Off Agenda, India Faces Russian Oil Tariff Risk

Trump-Xi summit (Sept 23-24, 2026) resulted in a symbolic but substance-light outcome. AI safety was dropped from talks, a 2-month trade truce extension was agreed, and India faces increased tariff pressure for buying Russian crude oil as China gets a temporary exemption. The summit reinforces India's suspicion that it is the primary US target under the Lindsey O. Graham Sanctioning Russia and Iran Act.

Intl. Relations Current Affairs

Xi Jinping at 18th BRICS Summit in Delhi; India's $112 Bn Deficit with China and US Tariff Risks

Xi Jinping visits India after 7 years for the 18th BRICS Summit, as India navigates a widening $112 billion trade deficit with China and US scrutiny on tariff circumvention. India's BRICS chairship aims to build production capacity, balancing Chinese investment and American market access.

Start Today's Quiz(25 Qs)

Take Today's Quiz

25 Qs • 5-7 Mins

US Imposes 100% Tariff on Patented Pharma from July 31; India's $9.7 Billion Exports Mainly Generic

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

National Security Tariff

India's Generic Shield

Strategic Pressure Tool

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance